A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Birabresib (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors OncoEthix
- 24 Mar 2017 Status changed from active, no longer recruiting to completed.
- 20 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.
- 20 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History